Gufic Biosciences (509079) investor relations material

Executive summary

• FY 2026 was a transition year with full fixed costs of a new facility, working capital restructuring, and significant investments in leadership, setting up for stronger performance in FY 2027.

• Q4 FY 2026 marked the strongest quarter ever, with record revenue and profitability, driven by operational improvements and strategic shifts.

• Achieved commercial production at the advanced Indore facility, targeting global regulated markets and complex injectables.

• Strong execution across hospital injectables, women's health, aesthetics, and chronic care platforms, with significant product launches and operational milestones.

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, showing continued profitability and growth in revenue and net profit year-over-year.

Financial highlights

• FY 2026 revenue reached INR 940.5 crore, up from INR 820 crore in FY 2025.

• Q4 FY 2026 revenue was INR 252 crore, a 23% increase year-over-year.

• Q4 EBITDA rose to INR 44.77 crore (margin 17.73%), up from INR 27 crore (margin 13.17%) in Q4 FY 2025.

• FY 2026 EBITDA was INR 152.9 crore (margin 16.26%), slightly down from 16.91% in FY 2025.

• Q4 PAT more than doubled to INR 20.5 crore, with PAT margin rising to 8.3%.

Outlook and guidance

• Management expects 15% year-over-year revenue growth and 0.5%-1% annual gross margin improvement.

• EBITDA margin is projected to reach 18% in FY 2027, with a long-term target above 20% by 2030.

• No major greenfield CapEx planned for the next two years; only maintenance CapEx of INR 20 crore annually.

• Indore facility expected to reach 30% utilization and EBITDA breakeven in FY26, with margin accretion from FY27.

• At peak utilization, Indore can generate Rs 675-700 Cr annual revenue.